RT Journal Article
T1 Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
A1 Shah, Jatin
A1 Shacham, Sharon
A1 Kauffman, Michael
A1 Daniele, Patrick
A1 Tomaras, Dimitrios
A1 Tremblay, Gabriel
A1 Casasnovas, Rene-Olivier
A1 Maerevoet, Marie
A1 Zijlstra, Josee
A1 Follows, George
A1 P Vermaat, Joost S
A1 Kalakonda, Nagesh
A1 Goy, Andre Henri
A1 Choquet, Sylvain
A1 Den Neste, Eric Van
A1 Hill, Brian T
A1 Thieblemont, Catherine
A1 Cavallo, Federica
A1 la Cruz, Fátima de
A1 Kuruvilla, John
A1 Hamad, Nada
A1 Bouabdallah, Reda
A1 Jäger, Ulrich
A1 Caimi, Paolo
A1 Gurion, Ronit
A1 Warzocha, Krzysztof
A1 Bakhshi, Sameer
A1 Sancho, Juan Manuel
A1 Schuster, Michael
A1 Egyed, Miklós
A1 Offner, Fritz
A1 Vasilakopoulos, Theodoros P
A1 Samal, Priyanka
A1 Nagy, Agnes
A1 Ku, Matthew
A1 Canales Albendea, Miguel Ángel
K1 EQ-5D-5L
K1 FACT-Lym
K1 diffuse large B-cell lymphoma
K1 disutility of adverse events
K1 health state utility
K1 health utility
K1 health-related quality of life
K1 patient-reported outcomes
K1 selinexor
AB Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p 
YR 2021
FD 2021-02-02
LK http://hdl.handle.net/10668/17083
UL http://hdl.handle.net/10668/17083
LA en
DS RISalud
RD Apr 19, 2025